ea0081rc14.4 | Rapid Communications 14: Late Breaking | ECE2022
Teresa Fuss Carmina
, Hartmann Oliver
, Reissland Michaela
, Pahor Nikolett
, Landwehr Laura-Sophie
, Fassnacht Martin
, Diefenbacherc Markus E
Adrenocortical carcinoma (ACC) is a rare malignancy with an incidence of 0.72.0 per million per year. Prognosis of ACC is generally poor but variable and therapeutic approaches are scarce. While surgical resection presents the best option for definitive cure, mitotane remains the only approved drug for adjuvant therapy in ACC to date. Advancements regarding novel treatment strategies as well as fostered understanding of potential drivers of adrenocortical carcinogenesis ...